| 摘要 |
PROBLEM TO BE SOLVED: To provide stable pharmaceutical formulations comprising monoclonal antibodies.SOLUTION: The present invention provides antibody formulations, including monoclonal antibodies formulated in a histidine-acetate buffer (pH 5.5-6.5), as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab). Preferably, the pH is from 5.8 to 6.2, the monoclonal antibody is an IgG1 antibody, and the concentration of the monoclonal antibody is about 10 to about 250 mg/mL.SELECTED DRAWING: None |
